[ Inside the business ]
BDX stock analysis
BDX · Becton Dickinson & Co
Surgical and medical instruments and apparatus. Growing 5%. Keeps 11¢ of every dollar.
Nothing unusual in its latest filings.
The future, in 7 questions
Priced in: 1.0× sales in 5 yrs. Evidence: sales +5% · 11¢ profit/$1.
Not among the companies mentioning Radar's technologies most.
- Moves strongly with the Dollar
From SEC filings, price and Radar. Not advice.
The record
Early signals
Growth speeding up.
Sales growth +2%, +5%, then +5% vs. a year ago.
Early signals
Growth speeding up.
Sales growth vs. a year ago, by quarter ending
What just happened
Signals in the filings
Early signals· full write-up
Growth speeding up.
Early signals Improving
What's changing in the filings before it shows up in yearly results. Signals, not predictions.
New since last 10-Q (Aug 6, 2026)
Nov 5, 2026 · Results announced. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. From 8-KGrowth momentum: sales vs. a year ago, by quarter Calculated
Signals in the filings
What could go wrong
Steadier than most.
It has moved 0.5× the market. In the 2008 crisis it fell 24% while the market fell 51%. Debt is heavy.
What could go wrong
Steadier than most.
Red-flag scan, last 3 years
Past shocks replayed stock S&P 500
Cash vs. debt
What could go wrong· full write-up
Steadier than most.
8 · What could go wrong
Warning signs in the filings, debt, how it reacts to the economy, and the risks it names
Red-flag scan, last 3 years
Modeled on the SEC's published Accounting Quality Model description, not SEC scores
Debt and leverage as of Jun 30, 2026
Macro risk 118 months to Oct 2026 Calculated
Stress test: past shocks replayed stock vs. S&P 500, month-end prices
Right now: last 3 months Reported
What if the market falls?
Historically, about -9% for this stock
Based on its 0.46× pattern. Real moves vary a lot, as the stress test shows.
Biggest risks it names
- No customer accounted for 10% or more of revenues in any of the three years presented. From 10-K
Full list: risk factors in the 10-K (Item 1A)
Speculative check
Self-funding.
Passes every condition: profitable, cash-generating and financially sound.
Speculative check
Self-funding.
All 14 tests passed or excused. Price is 2.6× yearly revenue.
Speculative check· full write-up
Self-funding.
Speculative check: does the business pay for itself?
Self-funding: every condition true, across all three statements. Income statement: revenue of $100M or more, a gross profit, an operating profit, a net profit (last 12 months) and a profit in the latest quarter. Balance sheet: current ratio of 1 or more, positive equity, debt manageable (cash at least the debt, or debt no more than 4 years of operating profit before depreciation). Cash flow: positive cash from operations and positive free cash flow. Plus: new shares under 5% a year, no going-concern warning, Altman Z-score out of the distress zone and a Piotroski F-score of 4 or more. Companies with both profits and positive operating cash are excused negative equity and a low Altman score (buybacks), a current ratio under 1 and negative free cash flow (heavy investment). Speculative: an operating loss, cash flowing out of operations and under $1B in sales (however much cash it has raised, even if one-off gains made a net profit); or a going-concern warning; or a penny stock (under $5 a share with under $6M revenue). Not classified: everything else, with the reasons listed. Tests that don't apply (like gross margin for banks) are left out. Calculated
Verdict: Self-funding, 0 of 14 tests red. Numbers to Jun 30, 2026. Calculated
Net profit: $942M (last 12 months). Is it making money after all costs? Losses aren't bad by themselves, but they mean someone else pays for now. Reported
Operating profit: $2.4B (last 12 months). Does the business itself make money, before interest, tax and one-off gains? A net profit with an operating loss usually means the profit came from outside the business. Reported
Gross margin: 47% (after the direct cost of what it sells). Does it make money on each sale before overhead? A negative gross margin means every sale loses money. Calculated
Revenue: $22.5B (last 12 months). Is the business big enough to stand on its own? Under $100 million a year counts as small; under $20 million as tiny. Reported
Cash from operations: $3.4B (last 12 months). Does the day-to-day business bring cash in, or use it up? Reported
Cash runway: Self-funded (free cash flow $2.6B a year). If it burns cash, how long until it runs out without raising more money? Cash includes short-term investments; burn is cash from operations minus spending on equipment. Calculated
Debt vs. cash: $16.8B debt ($708M cash · 3.5× yearly operating profit). Could it pay off its debt? Green when cash covers the debt or debt is under 2 years of operating profit (before depreciation). Reported
Current ratio: 0.9× (below 1×, but operating cash covers its bills). Can it pay the bills due within a year from short-term assets? Below 1× means it can't, without new money. Calculated
Shareholders' equity: $24.4B (assets exceed debts). Do its assets exceed everything it owes? Negative equity can come from years of losses or from big buybacks, so check which. Reported
New shares issued: +0.0% a year (share count over the last 2 years). Is it selling new shares to survive? Fast-rising share counts shrink each owner's slice. Uses diluted shares from annual reports. Calculated
Going-concern warning: None (in the latest annual report). Auditors must warn when they doubt a company can keep operating for the next year. Any such warning makes the verdict Speculative. From 10-K
Latest quarter profit: $377M (quarter to 2026-06-30). The S&P 500 asks for a profit in the latest quarter as well as over the last four. A loss in the latest quarter can be the first sign of trouble, or a one-off. Reported
Altman Z-score: 2.4 (grey zone). Edward Altman's bankruptcy-risk score from working capital, retained earnings, operating profit, market value and sales. Under 1.8 (1.1 for non-manufacturers) is the distress zone. Reported
Piotroski F-score: 7 of 9 (profit, cash, debt, liquidity, dilution, margins, efficiency vs. last year). Joseph Piotroski's nine pass/fail checks, this year vs. last: profit, operating cash, rising return on assets, cash above profit, less debt, better liquidity, no new shares, better margins, better asset turnover. 0–3 is weak, 7–9 strong. Reported
Benjamin Graham's defensive test (for reference, not part of the verdict): passes 4 of 7. ✓ Sales of $700M or more (his $100M in 1972 money) · ✗ Current ratio of 2 or more · ✗ Long-term debt no more than working capital · ✓ A profit every year (last 10) · ✓ Dividends every year (last 10) · ✓ Earnings up a third or more over the decade (3-year averages) · ✗ Price × earnings × book value moderate (P/E × P/B ≤ 22.5)
Price vs. sales: the market values it at 2.6× its yearly revenue. This is about the stock price, not the business, so it isn't one of the tests. Calculated
A label for learning, not a recommendation. Speculative companies can succeed and self-funding ones can fall.
What they sell
Not broken out.
The filings don't split revenue by product in structured data.
What they sell
Not broken out.
Not broken out by product in its structured filings.
What they sell· full write-up
Not broken out.
1 · What they sell
Not available: the company's filings don't break revenue down by product or segment in structured data.
Rivals it names: In some instances, competitors, including pharmaceutical companies, also offer (or are attempting to develop) alternative therapies for disease states that may be delivered without a medical device, such as oral GLP-1 medications. From 10-K
Where each dollar goes
11¢ profit.
53¢ to make what it sells, 36¢ on research and overhead, 11¢ left over. Revenue $22.5B in the last 12 months.
Where each dollar goes
11¢ profit.
Out of each $1 of $22.5B revenue
Where customers are
Where each dollar goes· full write-up
11¢ profit.
3 · Where each $1 goes last 12 months to Jun 30, 2026
$22.5B revenue Reported
Out of each $1 of revenue Reported
- Making the products53¢
- Research and development6¢
- Sales and admin25¢
- Other operating costs6¢
- Operating profit11¢
Where customers are fiscal year to Sep 30, 2025 Reported
Note: using fiscal year 2025 data. More recent figures not found in the latest quarterly filing.
Its market
0.3× the economy.
The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.
Its market
0.3× the economy.
Output growth a year, 2025–35, after inflation
Its market· full write-up
0.3× the economy.
2 · Where its markets head (10 years)
U.S. industry output growth after inflation, 2025–35
Projected to grow slower than the economy. Jobs in the industry: -0.2% a year. Gov projection
U.S. Bureau of Labor Statistics, Employment Projections 2025–35 (Table 2.11), released Aug 27, 2026
Market size and share
Your call.
There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.
Market size and share
Your call.
4 · Market size and share
Not available: no market size was found in the company's SEC filings. Companies usually give these in investor presentations, which aren't part of their official filings.
Market capture
Needs a market size (above). Nothing is assumed.
Life cycle
Maturity.
It earns cash, still invests, and pays back more than it borrows.
Life cycle
Maturity.
Life cycle stage Maturity
Where the company sits, based only on its financials
BDX, last 12 months to Dec 31, 2025 Reported
Cash pattern (+ − −) = maturity. Inferred
Path over time
Earnings quality
Clean.
Its numbers don't resemble those of past manipulators.
Earnings quality
Clean.
Beneish M-score: -2.81
Fraud-pattern scores by year · BDX
| Year | M-score | M zone | F-score | F risk |
|---|---|---|---|---|
| FY20 | −2.61 | 🟢 Clean | 1.48 | 🟠 About normal |
| FY21 | −2.73 | 🟢 Clean | 1.52 | 🟠 Above normal |
| FY22 | −2.58 | 🟢 Clean | 1.64 | 🟠 Above normal |
| FY23 | −2.44 | 🟢 Clean | 1.54 | 🟠 Above normal |
| FY24 | −2.57 | 🟢 Clean | 1.57 | 🟠 Above normal |
| FY25 | −2.81 | 🟢 Clean | 0.56 | 🟢 Normal |
M-score: flagged above −1.78, grey zone −2.22 to −1.78, clean below −2.22. F-score: 1.0 = an average company's risk, above 2.45 = high. Patterns to look into, not proof.
Cash checks
Earnings quality· full write-up
Clean.
5 · Earnings quality
Are the profits backed by cash?
How cautious are you? cost of a miss vs. a false alarm
Not flagged at cutoff -1.28
Vs. 6 peers (Surgical & Medical Instruments & Apparatus): #7 highest · peer median -2.62 · 0 in the high zone Calculated
Fiscal years to Sep 30, 2025 and Sep 30, 2024 · Beneish (1999)
Its fiscal 2025 numbers look 0.6× as much like past SEC fraud cases as an average company's.
Mostly from hard-to-value assets (87% of assets).
| Fiscal year | Beneish M-score | M zone | Dechow F-score | F risk |
|---|---|---|---|---|
| FY2020 | −2.61 | 🟢 Clean | 1.48 | 🟠 About normal |
| FY2021 | −2.73 | 🟢 Clean | 1.52 | 🟠 Above normal |
| FY2022 | −2.58 | 🟢 Clean | 1.64 | 🟠 Above normal |
| FY2023 | −2.44 | 🟢 Clean | 1.54 | 🟠 Above normal |
| FY2024 | −2.57 | 🟢 Clean | 1.57 | 🟠 Above normal |
| FY2025 | −2.81 | 🟢 Clean | 0.56 | 🟢 Normal |
Each year compared with the one before. “Off the scale” usually means a merger, spin-off or restructuring that year. Beneish (1999); Dechow, Ge, Larson & Sloan (2011), model 1.
Competitive advantage
1 of 10 years.
Returns beat its 6.2% cost of capital in 1 of the last 10 years. Gross margin went from 48% to 45%.
Competitive advantage
1 of 10 years.
Return on capital by year, vs. its cost of capital
Competitive advantage· full write-up
1 of 10 years.
6 · Competitive advantage
Can competitors erode its returns? Evidence, not a verdict.
Return on capital by fiscal year; dashed line = 6.2% cost of capital
Source of advantage, per the 10-K: · We can lose the protection afforded by these intellectual property assets through patent expirations, legal challenges or governmental action. From 10-K
Rivals it names: In some instances, competitors, including pharmaceutical companies, also offer (or are attempting to develop) alternative therapies for disease states that may be delivered without a medical device, such as oral GLP-1 medications. From 10-K
Future bets
6% on research.
$1.3B a year on R&D. $753M on equipment and buildings.
Future bets
6% on research.
Where the money for the years ahead goes
Future bets· full write-up
6% on research.
7 · Future bets
Where is it putting money for the years ahead? Plans and commitments, not outcomes.
All figures from Becton Dickinson & Co's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.